Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 17/20 | 0.61 |
| ▸ | PDE2A | O00408 | 2/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795533 | 0.91 | PDE10A (0.60) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL3658183 | 0.87 | PDE10A (0.55) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL3653120 | 0.85 | PDE10A (0.67) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL970643 | 0.85 | PDE10A (0.57) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL3660134 | 0.80 | PDE10A (0.55) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL3658809 | 0.80 | PDE10A (0.54) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL971026 | 0.78 | PDE10A (0.46) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL969580 | 0.78 | PDE10A (0.46) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL971116 | 0.77 | PDE10A (0.61) | PDE10APDE2APDE5APDE3APDE11A | |
| SCHEMBL3658808 | 0.76 | PDE10A (0.43) | PDE10APDE2APDE5APDE3APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227472-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Elbion Gmbh (DE) | 2010-09-15 | — | — | EP | claimed |
| WO-2009068320-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | WO | claimed |
| US-20090143391-A1 | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | claimed |
| EP-2227472-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Elbion Gmbh (DE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068320-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143391-A1 | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143391-A1 | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 | PDE12, PDE5A, PDE10A | PDE10A 3/4885PDE2A 6/4885PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.